The ongoing CONFIDENCE trial (NCT05254002) is designed to prospectively assess the albuminuria-lowering effects of monotherapy with the SGLT2 inhibitor empagliflozin, finerenone and their combination in 807 adults with T2D and CKD [46]. This evidence concerns the gene SLC5A2 and chronic kidney disease.